Viral vectors for gene therapy in Parkinson's disease

Reviews in the Neurosciences

Volumn 12, Issue 1, 2001, Pages 69-78

  Latchman, D S ^a   Coffin, R S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Gene therapy; Herpes simplex virus; Neurological diseases; Parkinson's disease; Viral vectors

Indexed keywords

DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; NEUROTROPHIC FACTOR; TYROSINE 3 MONOOXYGENASE; VIRUS VECTOR;

GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VIRUS GENE;

EID: 0035123708     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.2001.12.1.69     Document Type: Review

References (46)

1. Construction and characterization of a herpes simplex virus type I mutant unable to transduce immediate-early gene expression
2. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts
3. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease
4. Transfer and expression of the lac Z gene in rat brain neurons by herpes simplex virus mutants
5. Gene delivery to cardiac cells in vitro and in vivo using herpes simplex virus vectors
6. Herpes simplex virus based vectors
7. A latent nonpathogenic HSV-1 derived vector stably expresses β-galactosidase in mouse neurons
8. In vivo deletion analysis of the herpes simplex virus type I latency associated transcript promoter
9. Long-term behavioural recovery in parkinsonian rats by an HSV vector expressing tyrosine hydoxylase
10. Gene transfer to neurons using herpes simplex virus-based vectors
11. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-Dopa
12. Prospects for gene therapy in Parkinson's disease
13. Human gene therapy
14. Herpes simplex virus Vmw65-octamer binding protein interaction: A paradigm for combinatorial control of transcription
15. A novel latency-associated promoter is continued within the herpes simplex virus type 1 UL flanking repeats
16. Herpes simplex virus latent RNA (Lat) is not required for latent infection in the mouse
17. Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease
18. High efficiency gene transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional ICP27 and ICP34.5
19. Induction of midbrain dopaminergic neurons by sonic hedgehog
20. Intracerebral transplants of primary muscle cells: A potential 'platform' for transgene expression in the brain
21. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
22. Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders
23. Biology of glial cell line-derived neurotrophic factor (GDNF): Implications for the use of GDNF to treat Parkinson's disease
24. Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS
25. Molecular biology of herpes simplex virus latency
26. Herpes simplex virus vectors for gene therapy
27. A glial cell-derived neurotrophic factor for midbrain dopaminergic neurons
28. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease
29. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate-early gene 1 and the 'a' sequence
30. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease
31. Decreased reporter gene expression during latent infection with HSV LAT promoter constructs
32. Pathways of viral gene expression during acute neuronal infection with HSV-1
33. Human gene therapy comes of age
34. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
35. Fetal nigral transplantation as a therapy for Parkinson's disease
36. Development and optimisation of herpes simplex virus vectors for multiple long term gene delivery to the peripheral nervous system
37. Therapeutic replication competent herpes virus
38. An inquiry into the mechanisms of herpes simplex virus latency
39. Transplantation of genetically modified non-neuronal cells in the central nervous system
40. Bcl-2 transcription from the proximal p2 promoter is activated in neuronal cells by the Brn-3a POU family transcription factor
41. Equine herpes virus 1 gene 12 can substitute for Vmw65 in the growth of herpes simplex virus 1 (HSV1) allowing the generation of optimised cell lines for the propagation of vectors with multiple immediate-early gene defects
42. Direct injection of plasmid DNA into the brain
43. Protection of neuronal cells from apoptosis by hsp27 delivered with a herpes simplex virus-based vector
44. Intracerebral recombinant HSV-1 vector does not reactivate latent HSV-1
45. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)